Drugs / Peripheral Blood Stem Cell
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07046078 | Sep 2025 → Jun 2027 expected | acute leukemia of ambiguous lineage, chronic myelomonocytic leukemia, myelodysplastic syndrome | Fred Hutchinson Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT03970096 | Nov 2019 → Dec 2027 expected | acute lymphoblastic leukemia, acute myeloid leukemia, myelodysplastic syndrome | Fred Hutchinson Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT02143830 | Apr 2014 → Dec 2026 expected | Fanconi anemia, acute myeloid leukemia, bone marrow failure syndrome, myelodysplastic syndrome | Children's Hospital Medical Center, Cincinnati | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Peripheral blood stem cell | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02143830 ↗ |
| Modality | Cell therapy | “a CD34+ selected T-cell depleted peripheral blood stem cell (PBSC) stem cell transplant” NCT02143830 ↗ |
| Route | Intravenous | “Given IV” NCT03970096 ↗ |